PALM INTRANET

Day : Wednesday
Date: 4/12/2006
Time: 15:18:03

Inventor Information for 10/031478

Inventor Name	City	State/Country
BARNHAM, KEVIN JEFFREY	WEST BRUNSWICK	AUSTRALIA
MCCARTHY, THOMAS DAVID	MALVERN EAST	AUSTRALIA
PALLICH, SUSANNE	CAROLINE SPRINGS	AUSTRALIA
MATTHEWS, BARRY ROSS	OLINDA	AUSTRALIA
CHERNY, ROBERT ALAN	BRIGHTON EAST	AUSTRALIA

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data | Inver

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L5	2	"6323218".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:21
L6	54395	Alzheimer$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:21
L7	13503	amyloid$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:22
L8	9352	l6 and l7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:22
L9	1150	l8 (chelator or chelation)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:22
L10	15	l9 and (chelation adj therapy)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 15:22
S1	1	wo-200107442-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 12:22
S2	1	2001-168531.NRAN.	DERWENT	AND	ON	2006/04/11 20:11
S3	2	wo-9628471-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/04/12 14:48
S4	1	1996-433762.NRAN.	DERWENT	AND	ON	2006/04/12 12:28

```
> d his ful

     (FILE 'HOME' ENTERED AT 09:07:40 ON 12 APR 2006)

     FILE 'REGISTRY' ENTERED AT 09:07:55 ON 12 APR 2006
               E BR7158/CN

     FILE 'HCAPLUS' ENTERED AT 09:08:25 ON 12 APR 2006
L1             0 SEA PLU=ON  BR7158

     FILE 'REGISTRY' ENTERED AT 09:08:42 ON 12 APR 2006
               E BRI7158/CN

     FILE 'HCAPLUS' ENTERED AT 09:08:55 ON 12 APR 2006
L2             0 SEA PLU=ON  BRI7158

     FILE 'REGISTRY' ENTERED AT 09:09:19 ON 12 APR 2006
L3          2595 SEA PLU=ON  LVFFA/SQSP
L4           131 SEA PLU=ON  LVFFA^/SQSP
L5            98 SEA PLU=ON  LVFFA^/SQEP

     FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 09:11:08 ON 12 APR 2006
L6            47 SEA PLU=ON  L5
L7            38 DUP REM L6 (9 DUPLICATES REMOVED)
                    ANSWERS '1-22' FROM FILE HCAPLUS
                    ANSWERS '23-38' FROM FILE USPATFULL
L8            22 SEA PLU=ON  L7 AND (PD<20000721 OR PRD<20000721)
L9            10 SEA PLU=ON  L8 AND PD<19990721
                 D L9 1-10 IBIB ABS HITSTR
L10           12 SEA PLU=ON  L8 NOT L9
                 D L10 1-12 IBIB ABS HITSTR
                 D QUE STA

     FILE 'REGISTRY' ENTERED AT 09:16:57 ON 12 APR 2006
L11            1 SEA PLU=ON  321913-17-1/RN
                 D L11 SQIDE TOTAL

     FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 09:17:00 ON 12 APR 2006


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   10 APR 2006  HIGHEST RN 879997-63-4
     DICTIONARY FILE UPDATES:  10 APR 2006  HIGHEST RN 879997-63-4

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ******************************************************************
     *                                                                *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,  *
     * effective March 20, 2005.  A new display format, IDERL, is now   *
```

* available and contains the CA role and document type information. *
*   *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

FILE COVERS 1907 - 12 Apr 2006 VOL 144 ISS 16
FILE LAST UPDATED: 11 Apr 2006 (20060411/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Apr 2006 (20060406/PD)
FILE LAST UPDATED: 6 Apr 2006 (20060406/ED)
CA INDEXING IS CURRENT THROUGH 6 Apr 2006 (20060406/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Apr 2006 (20060406/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006

FILE USPAT2
FILE COVERS 2001 TO PUBLICATION DATE: 11 Apr 2006 (20060411/PD)
FILE LAST UPDATED: 11 Apr 2006 (20060411/ED)
CA INDEXING IS CURRENT THROUGH 11 Apr 2006 (20060411/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 11 Apr 2006 (20060411/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006

```
=> d que sta
L11           1 SEA FILE=REGISTRY PLU=ON  321913-17-1/RN


=> d que sta l10
L5           98 SEA FILE=REGISTRY PLU=ON  LVFFA^/SQEP
L6           47 SEA L5
L7           38 DUP REM L6 (9 DUPLICATES REMOVED)
L8           22 SEA L7 AND (PD<20000721 OR PRD<20000721)
L9           10 SEA L8 AND PD<19990721
L10          12 SEA L8 NOT L9
```

> d l9 1-10 ibib abs hitstr

L9 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:844884 HCAPLUS
DOCUMENT NUMBER: 136:665
TITLE: Modified peptide modulators of amyloid aggregation
INVENTOR(S): Findeis, Mark A.; Benjamin, Howard; Garnick, Marc B.; Gefter, Malcolm L.; Hundal, Arvind; Kasman, Laura; Musso, Gary; Signer, Ethan R.; Wakefield, James; Reed, Michael J.
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA
SOURCE: U.S., 54 pp., Cont.-in-part of U.S. Ser. No. 548,998, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6319498	B1	20011120	US 1996-617267	19960314 <--
US 5817626	A	19981006	US 1995-404831	19950314 <--
US 5854215	A	19981229	US 1995-475579	19950607 <--
AU 759036	B2	20030403	AU 2000-35389	20000519 <--
US 2002098173	A1	20020725	US 2001-972475	20011004 <--
AU 769915	B2	20040212	AU 2002-15539	20020211 <--
US 2004005307	A1	20040108	US 2003-463729	20030617 <--
AU 2003208150	A1	20030807	AU 2003-208150	20030703 <--
AU 2004202014	A1	20040610	AU 2004-202014	20040512 <--

PRIORITY APPLN. INFO.:

US 1995-404831	A2	19950314 <--
US 1995-475579	A2	19950607 <--
US 1995-548998	B2	19951027 <--
AU 1996-52524	A3	19960314 <--
US 1996-617267	A1	19960314 <--
AU 1997-42387	A3	19970827 <--
AU 2000-35389	A3	20000519 <--
US 2001-972475	A1	20011004
AU 2002-15539	A3	20020211

OTHER SOURCE(S): MARPAT 136:665
AB Compds. that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compds. modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compds. are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.
IT **182912-78-3 182912-78-3D**, N-terminal cholyl derivs.
183746-77-2 183746-77-2D, N-terminal cholyl derivs.
183746-96-5 204333-52-8D, N-terminal cholyl derivs.
321913-13-7D, N-terminal cholyl derivs. **365537-66-2D**, N-terminal cholyl derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(modified peptide modulators of amyloid aggregation)

RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-96-5 HCAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-52-8 HCAPLUS
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321913-13-7 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-66-2 HCAPLUS
CN D-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **365537-66-2**
RL: PRP (Properties)
(unclaimed sequence; modified peptide modulators of amyloid aggregation)
RN 365537-66-2 HCAPLUS
CN D-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:757810 HCAPLUS
DOCUMENT NUMBER: 135:298818
TITLE: D-amino acid-containing peptide modulators of β-amyloid peptide aggregation
INVENTOR(S): Findeis, Mark A.; Gefter, Malcolm L.; Musso, Gary;

Signer, Ethan R.; Wakefield, James; Molineaux, Susan; Chin, Joseph; Lee, Jung-Ja; Kelley, Michael; Komar-Panicucci, Sonja; Arico-Muendel, Christopher C.; Phillips, Kathryn; Hayward, Neil J.

PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., USA

SOURCE: U.S., 44 pp., Cont.-in-part of U.S. Ser. No. 616,081.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6303567	B1	20011016	US 1996-703675	19960827 <--
US 5817626	A	19981006	US 1995-404831	19950314 <--
US 5854215	A	19981229	US 1995-475579	19950607 <--
CA 2262453	AA	19980305	CA 1997-2262453	19970827 <--
WO 9808868	A1	19980305	WO 1997-US15166	19970827 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9742387	A1	19980319	AU 1997-42387	19970827 <--
AU 741199	B2	20011122		
EP 929574	A1	19990721	EP 1997-940663	19970827 <--
EP 929574	B1	20050629		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 5985242	A	19991116	US 1997-920162	19970827 <--
JP 2001500852	T2	20010123	JP 1998-511914	19970827 <--
AT 298765	E	20050715	AT 1997-940663	19970827 <--
EP 1586584	A1	20051019	EP 2005-13789	19970827 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, AL				
PT 929574	T	20051130	PT 1997-940663	19970827 <--
ES 2245003	T3	20051216	ES 1997-940663	19970827 <--
US 6277826	B1	20010821	US 1999-356931	19990719 <--
HK 1021741	A1	20060217	HK 2000-100377	20000120 <--
AU 759036	B2	20030403	AU 2000-35389	20000519 <--
US 2002103134	A1	20020801	US 2001-895443	20010629 <--
US 6689752	B2	20040210		
AU 769915	B2	20040212	AU 2002-15539	20020211 <--
AU 2003208150	A1	20030807	AU 2003-208150	20030703 <--
US 2006014696	A1	20060119	US 2003-677076	20030930 <--
AU 2004202014	A1	20040610	AU 2004-202014	20040512 <--

PRIORITY APPLN. INFO.:			
US 1995-404831	A2	19950314	<--
US 1995-475579	A2	19950607	<--
US 1995-548998	B2	19951027	<--
US 1996-616081	B2	19960314	<--
AU 1996-52524	A3	19960314	<--
US 1996-703675	A	19960827	<--
US 1997-897342	A	19970721	<--
AU 1997-42387	A3	19970827	<--
EP 1997-940663	A3	19970827	<--
US 1997-920162	A1	19970827	<--
WO 1997-US15166	W	19970827	<--

US 1999-356931 A1 19990719 <--
AU 2000-35389 A3 20000519 <--
US 2001-895443 A1 20010629
AU 2002-15539 A3 20020211

OTHER SOURCE(S): MARPAT 135:298818

AB Compds. that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from D-leucine, D-phenylalanine, and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21 . In certain embodiments, the peptide is modified at the amino-terminus, the carboxyl-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxyl-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group, and a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases (e.g. Alzheimer's disease) using the compds. of the invention, are also disclosed.

IT **183746-33-0P 183746-58-9P 183746-91-0P**
183903-87-9P 204333-81-3P 204333-82-4P
204333-83-5P 204333-84-6P 204333-86-8P
365538-46-1P 365538-52-9P 365538-53-0P
365538-55-2P 365538-56-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(D-amino acid-containing peptide modulators of β-amyloid peptide aggregation)

RN 183746-33-0 HCAPLUS

CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-58-9 HCAPLUS
CN L-Alaninamide, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-91-0 HCAPLUS
CN L-Alanine, N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183903-87-9 HCAPLUS
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-81-3 HCAPLUS
CN L-Alanine, N-[(3α,5β,6α)-3,6-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-82-4 HCAPLUS
CN L-Alanine, N-[(3α,5β,7α)-3,7-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-83-5 HCAPLUS
CN L-Alanine, N-[(3α,5β,7β)-3,7-dihydroxy-24-oxocholan-24-yl]-
L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-84-6 HCAPLUS
CN D-Alaninamide, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-86-8 HCAPLUS
CN D-Alaninamide, N-(1-oxobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365538-46-1 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 365538-52-9 HCAPLUS

CN D-Alaninamide, N-(2-methyl-1-oxopropyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365538-53-0 HCAPLUS
CN D-Alaninamide, N-(4-methyl-1-oxopentyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365538-55-2 HCAPLUS
CN L-Alaninamide, N-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

—NH_2

RN 365538-56-3 HCAPLUS
CN L-Alaninamide, hydroxyacetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **182912-78-3D**, amino-terminal modified derivs. **183746-77-2**
183746-77-2D, amino-terminal modified derivs. **204333-52-8**
204333-52-8D, alkyl- and aryl-amide derivs. **204333-53-9**
365534-27-6 365534-45-8 365534-71-0
365534-98-1 365535-35-9 365535-68-8
365535-86-0 365536-04-5 365536-22-7
365536-40-9 365536-61-4 365536-79-4
365536-97-6 365537-15-1 365537-38-8
365537-66-2D, modifying group derivs. **365537-67-3**
365537-67-3D, derivs. **365537-68-4 365537-68-4D**
, derivs. **365537-69-5 365537-69-5D**, derivs.
365537-71-9 365537-73-1 365537-75-3
365537-77-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(D-amino acid-containing peptide modulators of β-amyloid peptide aggregation)
RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-52-8 HCAPLUS
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-52-8 HCAPLUS
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-53-9 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365534-27-6 HCAPLUS
CN D-Alanine, N-[[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]oxy]acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365534-45-8 HCAPLUS
CN D-Alanine, N-(phenylacetyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365534-71-0 HCAPLUS
CN D-Alanine, N-(diphenylacetyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365534-98-1 HCAPLUS
CN D-Alanine, N-(triphenylacetyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365535-35-9 HCAPLUS
CN D-Alanine, N-(2-methyl-1-oxopropyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365535-68-8 HCAPLUS
CN D-Alanine, N-(4-methyl-1-oxopentyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365535-86-0 HCAPLUS
CN D-Alanine, N-[(3-hydroxyphenyl)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365536-04-5 HCAPLUS
CN D-Alanine, N-[(2-hydroxyphenyl)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365536-22-7 HCAPLUS
CN D-Alanine, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365536-40-9 HCAPLUS
CN D-Alanine, N-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 365536-61-4 HCAPLUS
CN D-Alanine, α-hydroxybenzeneacetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365536-79-4 HCAPLUS
CN D-Alanine, hydroxyacetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365536-97-6 HCAPLUS
CN D-Alanine, N-(1,4-dioxo-4-phenylbutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-15-1 HCAPLUS
CN D-Alanine, N-(2,4-dihydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-38-8 HCAPLUS
CN D-Phenylalaninamide, D-leucyl-D-valyl-D-phenylalanyl-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-66-2 HCAPLUS
CN D-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-67-3 HCAPLUS
CN L-Alanine, N-(4-hydroxybenzoyl)-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-67-3 HCAPLUS
CN L-Alanine, N-(4-hydroxybenzoyl)-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-68-4 HCAPLUS
CN L-Alanine, N-[(4-hydroxyphenyl)acetyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-68-4 HCAPLUS
CN L-Alanine, N-[(4-hydroxyphenyl)acetyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-69-5 HCAPLUS
CN L-Alanine, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-69-5 HCAPLUS
CN L-Alanine, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-71-9 HCAPLUS
CN L-Alanine, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CO_2H

RN 365537-73-1 HCAPLUS
CN L-Alaninamide, N-(4-hydroxybenzoyl)-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365537-75-3 HCAPLUS
CN L-Alaninamide, N-[(4-hydroxyphenyl)acetyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 365537-77-5 HCAPLUS
CN L-Alaninamide, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **182912-78-3**
RL: PRP (Properties)
(D-amino acid-containing peptide modulators of β-amyloid peptide aggregation)
RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:773575 HCAPLUS
DOCUMENT NUMBER: 132:220716
TITLE: Aged synthetic human amyloid β-peptide 1-42 and related fragments induce direct acetylcholine release from rat basal forebrain tissue slices
AUTHOR(S): Forgon, Monika; Farkas, Z.; Pakaski, Magdolna; Zarandi, Marta; Penke, B.
CORPORATE SOURCE: Alzheimer's Disease Research Centre, Albert Szent-Gyorgyi Medical University, Szeged, H-6720, Hung.
SOURCE: Acta Biologica Hungarica (**1998**), 49(1), 71-78
CODEN: ABHUE6; ISSN: 0236-5383
PUBLISHER: Akademiai Kiado
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The direct effects of synthetic human amyloid 1-peptide 1-42 (Aβ1-42), scrambled Aβ1-42 (MOD1 and MOD2), and related

fragments (Aβ31-35, Aβ34-39, and Aβ17-21), either freshly dissolved (non-aged) or aged for 2, 4, 12 and 24 h, were studied on acetylcholine release from rat basal forebrain tissue slices. In in vitro tissue slices, Aβ1-42 aged for 2 h, and Aβ31-35 and Aβ34-39 aged for 24 h evoked acetylcholine release from the basal forebrain tissue slices in a Ca2+-dependent manner. Transmitter release was not observed on the use of freshly dissolved Aβ1-42 and scrambled Aβ1-42 (MOD1 and MOD2) and Aβ17-21 aged for 24 h. These data support the suggestion that it is the fibrillar (aggregated) form which is effective on the axon terminals and evokes direct acetylcholine release. It is proposed that one of the roles of Aβ in the brain is the presynaptic modulation of acetylcholine release, in this way causing first an altered Ca2+-homeostasis, then cholinergic hypoactivity, and finally the retrograde degeneration of cholinergic nerve cells.

IT **182912-78-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(aged (fibrillar) synthetic human amyloid β-peptide 1-42 and related fragments induce direct acetylcholine release from rat basal forebrain tissue slices)

RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:278142 HCAPLUS
DOCUMENT NUMBER: 131:110884
TITLE: Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization
AUTHOR(S): Findeis, Mark A.; Musso, Gary M.; Arico-Muendel, Christopher C.; Benjamin, Howard W.; Hundal, Arvind M.; Lee, Jung-Ja; Chin, Joseph; Kelley, Michael; Wakefield, James; Hayward, Neil J.; Molineaux, Susan M.
CORPORATE SOURCE: PRAECIS Pharm. Inc., Cambridge, MA, 02139-1572, USA
SOURCE: Biochemistry (**1999**), 38(21), 6791-6800
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Cellular toxicity resulting from nucleation-dependent polymerization of amyloid β-peptide (Aβ) is considered to be a major and possibly the primary component of Alzheimer's disease (AD). Inhibition of Aβ polymerization has thus been identified as a target for the development of

therapeutic agents for the treatment of AD. The intrinsic affinity of Aβ for itself suggested that Aβ-specific interactions could be adapted to the development of compds. that would bind to Aβ and prevent it from polymerizing Aβ-derived peptides of fifteen residues were found to be inhibitory of Aβ polymerization The activity of these peptides was subsequently enhanced through modification of their amino termini with specific organic reagents. Addnl. series of compds. prepared to probe structural requirements for activity allowed reduction of the size of the inhibitors and optimization of the Aβ-derived peptide portion to afford a lead compound, cholyl-Leu-Val-Phe-Phe-Ala-OH (PPI-368), with potent polymerization inhibitory activity but limited biochem. stability. The corresponding all-D-amino acyl analog peptide acid (PPI-433) and amide (PPI-457) retained inhibitory activity and were both stable in monkey cerebrospinal fluid for 24 h.

IT **183746-33-0P 204333-43-7P 204333-44-8P 204333-48-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(modified peptide inhibitors of amyloid β-peptide polymerization and stability in monkey CSF)

RN 183746-33-0 HCAPLUS

CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-43-7 HCAPLUS
CN L-Alanine, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-44-8 HCAPLUS
CN L-Alaninamide, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-48-2 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:21679 HCAPLUS
DOCUMENT NUMBER: 130:95847
TITLE: Preparation of amyloid β peptides and derivatives that modulate β-amyloid aggregation
INVENTOR(S): Findeis, Mark A.; Benjamin, Howard; Garnick, Marc B.; Gefter, Malcolm L.; Hundal, Arvind; Kasman, Laura; Musso, Gary; Signer, Ethan R.; Wakefield, James; Reed, Michael; Molineaux, Susan; Kubasek, William; Chin, Joseph; Lee, Jung-Ja; Kelley, Michael
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., USA
SOURCE: U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 404,831.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5854204	A	19981229	US 1996-612785	19960314 <--
US 5817626	A	19981006	US 1995-404831	19950314 <--

US 5854215	A	19981229	US 1995-475579	19950607	<--
AU 759036	B2	20030403	AU 2000-35389	20000519	<--
AU 769915	B2	20040212	AU 2002-15539	20020211	<--
AU 2003208150	A1	20030807	AU 2003-208150	20030703	<--
AU 2004202014	A1	20040610	AU 2004-202014	20040512	<--
PRIORITY APPLN. INFO.:			US 1995-404831	A2 19950314	<--
			US 1995-475579	A2 19950607	<--
			US 1995-548998	A2 19951027	<--
			AU 1996-52524	A3 19960314	<--
			AU 1997-42387	A3 19970827	<--
			AU 2000-35389	A3 20000519	<--
			AU 2002-15539	A3 20020211	

AB Compds. that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compds. modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compds. of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.

IT **182912-78-3P 183746-33-0P 183746-58-9P**
183746-75-0P 183746-77-2P 183746-80-7P
183746-81-8P 183746-89-6P 183746-91-0P
183746-96-5P 183903-86-8P 183903-87-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amyloid β peptides and derivs. that modulate β-amyloid aggregation)

RN 182912-78-3 HCAPLUS

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-33-0 HCAPLUS

CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-58-9 HCAPLUS
CN L-Alaninamide, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-75-0 HCAPLUS
CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-80-7 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-N-[2-[[(3β,5β,7α,12α)-23-carboxy-7,12-dihydroxy-24-norcholan-3-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-81-8 HCAPLUS
CN L-Alanine, N-[(3β,5β,7α,12α)-3-(2-aminoethoxy)-7,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-89-6 HCAPLUS
CN L-Alanine, N-[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-91-0 HCAPLUS
CN L-Alanine, N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-96-5 HCAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183903-86-8 HCAPLUS
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183903-87-9 HCAPLUS
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:725680 HCAPLUS
DOCUMENT NUMBER: 130:91806
TITLE: Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster
AUTHOR(S): Zhang, Shengsheng; Casey, Nicole; Lee, Jonathan P.
CORPORATE SOURCE: Department of Chemistry, Boston University, Boston, MA, 02215, USA
SOURCE: Folding & Design (**1998**), 3(5), 413-422
CODEN: FODEFH; ISSN: 1359-0278
PUBLISHER: Current Biology Publications
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Structure-function studies on the Alzheimer's disease peptide show that a central hydrophobic cluster - Aβ(17-21), LVFFA - is a prominent structural feature linked to plaque competence. The origin and stability of this cluster was probed in a 17-residue fragment which includes flanking residues that potentially help stabilize the cluster. After residue substitution, the measurement of pKas, amide exchange rates and other NMR data show that any coulombic interactions between His 14 and Glu22 are not required for the stability of the central hydrophobic cluster. In contrast, a single substitution within the cluster disrupts

its integrity and causes the largest pKa shift for flanking residues, while increasing the solvent accessibility of the backbone. The integrity of the structurally dominant cluster relies primarily upon local hydrophobic interactions, rather than on interactions between the sidechains of charged flanking residues. Moreover, the conformational disposition of the cluster affects the pKas of flanking residues, underscoring its structural dominance.

IT **182912-78-3**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amyloid β central hydrophobic cluster peptide residual structure in Alzheimer's disease peptide)

RN 182912-78-3 HCAPLUS

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:163613 HCAPLUS
DOCUMENT NUMBER: 128:217639
TITLE: Preparation of D-amino acid peptides as modulators of β-amyloid peptide aggregation
INVENTOR(S): Findeis, Mark A.; Gefter, Malcolm L.; Musso, Gary; Signer, Ethan R.; Wakefield, James; Molineaux, Susan; Chin, Joseph; Lee, Jung-Ja; Kelley, Michael; Komar-Panicucci, Sonja; Arico-Muendel, Christopher C.; Phillips, Kathryn; Hayward, Neil J.
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808868	A1	19980305	WO 1997-US15166	19970827 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,

GN, ML, MR, NE, SN, TD, TG

US 6303567	B1	20011016	US 1996-703675	19960827 <--
CA 2262453	AA	19980305	CA 1997-2262453	19970827 <--
AU 9742387	A1	19980319	AU 1997-42387	19970827 <--
AU 741199	B2	20011122		
EP 929574	A1	19990721	EP 1997-940663	19970827 <--
EP 929574	B1	20050629		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2001500852	T2	20010123	JP 1998-511914	19970827 <--
AT 298765	E	20050715	AT 1997-940663	19970827 <--
HK 1021741	A1	20060217	HK 2000-100377	20000120 <--
AU 759036	B2	20030403	AU 2000-35389	20000519 <--
AU 769915	B2	20040212	AU 2002-15539	20020211 <--
AU 2003208150	A1	20030807	AU 2003-208150	20030703 <--
AU 2004202014	A1	20040610	AU 2004-202014	20040512 <--

PRIORITY APPLN. INFO.:

US 1996-703675	A	19960827 <--
US 1997-897342	A	19970721 <--
US 1995-404831	A2	19950314 <--
US 1995-475579	A2	19950607 <--
US 1995-548998	B2	19951027 <--
AU 1996-52524	A3	19960314 <--
US 1996-616081	B2	19960314 <--
AU 1997-42387	A3	19970827 <--
WO 1997-US15166	W	19970827 <--
AU 2000-35389	A3	20000519 <--
AU 2002-15539	A3	20020211

OTHER SOURCE(S): MARPAT 128:217639

AB Compds. that modulate natural β-amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β-amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-Leu, D-Phe, and D-Val. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β-amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkylamide group, an arylamide group or a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed. Thus, peptide H-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-NH2, prepared by standard solid-phase methods, inhibited aggregation of natural β-amyloid peptide with a change in lag time of 3.5 at a concentration of 3 μM.

IT **183746-91-0P 204333-38-0P 204333-39-1P**
204333-40-4P 204333-43-7P 204333-44-8P
204333-48-2P 204333-52-8P 204333-53-9P
204333-74-4P 204333-80-2P 204333-81-3P
204333-82-4P 204333-83-5P 204333-84-6P
204333-85-7P 204333-86-8P 204333-87-9P
204333-88-0P 204333-90-4P 204333-91-5P
204333-92-6P 204333-93-7P 204333-95-9P
204333-96-0P 204333-97-1P 204333-98-2P
204333-99-3P 204334-00-9P 204334-01-0P
204334-15-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of D-amino acid peptides as modulators of β-amyloid peptide aggregation)

RN 183746-91-0 HCAPLUS

CN L-Alanine, N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-38-0 HCAPLUS

CN D-Alaninamide, N-[(3α,5β,6α)-3,6-dihydroxycholan-24-oyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-39-1 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7α)-3,7-dihydroxycholan-24-oyl]-
D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-40-4 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7β)-3,7-dihydroxycholan-24-oyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-43-7 HCAPLUS
CN L-Alanine, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-44-8 HCAPLUS
CN L-Alaninamide, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-48-2 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7β,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-52-8 HCAPLUS
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-53-9 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-74-4 HCAPLUS
CN D-Alaninamide, N-acetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-80-2 HCAPLUS
CN D-Alaninamide, N-[[(hydroxyphenylacetyl)oxy]phenylacetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-81-3 HCAPLUS
CN L-Alanine, N-[(3α,5β,6α)-3,6-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-82-4 HCAPLUS
CN L-Alanine, N-[(3α,5β,7α)-3,7-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-83-5 HCAPLUS
CN L-Alanine, N-[(3α,5β,7β)-3,7-dihydroxy-24-oxocholan-24-yl]-
L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-84-6 HCAPLUS
CN D-Alaninamide, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-85-7 HCAPLUS
CN D-Alaninamide, N-(3-methyl-1-oxobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-86-8 HCAPLUS
CN D-Alaninamide, N-(1-oxobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-87-9 HCAPLUS
CN D-Alaninamide, N-(1-oxobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-88-0 HCAPLUS
CN D-Alaninamide, N-(2,4-dihydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-

phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-90-4 HCAPLUS
CN D-Alaninamide, hydroxyacetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-91-5 HCAPLUS
CN D-Alaninamide, N-[3-(2-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 204333-92-6 HCAPLUS
CN D-Alaninamide, N-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

NH2

RN 204333-93-7 HCAPLUS
CN D-Alaninamide, N-[3-(3-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

NH2

RN 204333-95-9 HCAPLUS
CN D-Alaninamide, N-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

—NH_2

RN 204333-96-0 HCAPLUS
CN D-Alaninamide, N-(3-formylbenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-97-1 HCAPLUS
CN D-Alaninamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 204333-98-2 HCAPLUS
CN D-Alaninamide, N-[(2-formylphenoxy)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-99-3 HCAPLUS
CN D-Alaninamide, N-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 204334-00-9 HCAPLUS
CN D-Alaninamide, N-(4-hydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204334-01-0 HCAPLUS
CN D-Alaninamide, N-[(4-hydroxyphenyl)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 204334-15-6 HCAPLUS
CN D-Alaninamide, α,4-dihydroxybenzenepropanoyl-D-leucyl-D-valyl-D-

phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:748345 HCAPLUS
DOCUMENT NUMBER: 126:19332
TITLE: Preparation of peptides as modulators of amyloid aggregation
INVENTOR(S): Findeis, Mark A.; Benjamin, Howard; Garnick, Marc B.; Gefter, Malcolm L.; Hundal, Arvind; Kasman, Laura; Musso, Gary; Signer, Ethan R.; Wakefield, James; et al.
PATENT ASSIGNEE(S): Pharmaceutical Peptides Incorporated, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9628471	A1	19960919	WO 1996-US3492	19960314 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5817626	A	19981006	US 1995-404831	19950314 <--
US 5854215	A	19981229	US 1995-475579	19950607 <--
AU 9652524	A1	19961002	AU 1996-52524	19960314 <--
EP 815134	A1	19980107	EP 1996-908805	19960314 <--
EP 815134	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11514333	T2	19991207	JP 1996-527816	19960314 <--

AT 218583	E	20020615	AT 1996-908805		19960314 <--
AU 759036	B2	20030403	AU 2000-35389		20000519 <--
AU 769915	B2	20040212	AU 2002-15539		20020211 <--
AU 2003208150	A1	20030807	AU 2003-208150		20030703 <--
AU 2004202014	A1	20040610	AU 2004-202014		20040512 <--
PRIORITY APPLN. INFO.:			US 1995-404831	A	19950314 <--
			US 1995-475579	A	19950607 <--
			US 1995-548998	A	19951027 <--
			AU 1996-52524	A3	19960314 <--
			WO 1996-US3492	W	19960314 <--
			AU 1997-42387	A3	19970827 <--
			AU 2000-35389	A3	20000519 <--
			AU 2002-15539	A3	20020211

AB Compds. that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compds. modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compds. of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed. These peptide compds. are bound to natural β-amyloid peptides to facilitate diagnosis of a β-amyloidogenic disease, in particular Alzheimer's disease, and are useful for treating a disorder associated with amyloidosis including, e.g. familial amyloid polyneuropathy or cardiomyopathy, isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, and Creutzfeldt-Jakob disease. Thus, N-biotinyl-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH (N-biotinyl-β-AP1-40), prepared by the solid phase synthesis using a Nα-Fmoc-based protection strategy and Fmoc-Val-Wang resin, at 1% markedly inhibited aggregation of the natural β-amyloid peptide (β-AP1-40).

IT **182912-78-3P 183746-33-0P 183746-58-9P**
183746-75-0P 183746-77-2P 183746-80-7P
183746-81-8P 183746-89-6P 183746-91-0P
183746-96-5P 183903-86-8P 183903-87-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as modulators of amyloid aggregation for treating amyloidosis-associated disorders)

RN 182912-78-3 HCAPLUS

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-33-0 HCAPLUS
CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-58-9 HCAPLUS
CN L-Alaninamide, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-75-0 HCAPLUS
CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-77-2 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-80-7 HCAPLUS
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-N-[2-[[(3β,5β,7α,12α)-23-carboxy-7,12-dihydroxy-24-norcholan-3-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-81-8 HCAPLUS
CN L-Alanine, N-[(3β,5β,7α,12α)-3-(2-aminoethoxy)-7,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-89-6 HCAPLUS
CN L-Alanine, N-[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-91-0 HCAPLUS
CN L-Alanine, N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-96-5 HCAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183903-86-8 HCAPLUS
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183903-87-9 HCAPLUS
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:592336 HCAPLUS
DOCUMENT NUMBER: 125:292787
TITLE: Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation
AUTHOR(S): Soto, Claudio; Kindy, Mark S.; Baumann, Marc; Frangione, Blas
CORPORATE SOURCE: Dep. Neurology, Dep. Pathology, New York Univ. Med. Center, New York, NY, 10016, USA
SOURCE: Biochemical and Biophysical Research Communications (**1996**), 226(3), 672-680
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Amyloid β-peptide (Aβ) is a major fibrillar component of neuritic plaques in Alzheimer's disease (AD) brains and is related to the pathogenesis of the disease. We hypothesized that amyloid formation could be inhibited by peptides homologous to Aβ (position 17-21) with a similar degree of hydrophobicity, but with a very low propensity to adopt a β-sheet conformation by incorporating proline residues (anti-β-sheet peptides or β-sheet inhibitors). An 11-residue peptide with these characteristics binds to Aβ, inhibits Aβ fibril formation, and partially disaggregates preformed fibrils in vitro.

Shorter anti-β-sheet peptides and analogs containing D-amino acids are also able to inhibit Aβ fibrillogenesis. The latter are more resistant to proteolytic degradation and may serve as a starting point ot design more efficient peptides derivs. to inhibit amyloidogenesis in vivo.

IT **182912-78-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(amyloid β-peptide (17-21) fragment sequence; Alzheimer's amyloidosis inhibition by peptides homologous to amyloid β-peptide and preventing β-sheet conformation)

RN 182912-78-3 HCAPLUS

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER:	1998:122377 USPATFULL
TITLE:	Modulators of beta-amyloid peptide aggregation
INVENTOR(S):	Findeis, Mark A., Boston, MA, United States Benjamin, Howard, Lexington, MA, United States Garnick, Marc B., Brookline, MA, United States Gefter, Malcolm L., Lincoln, MA, United States Hundal, Arvind, Brighton, MA, United States Kasman, Laura, Athens, GA, United States Musso, Gary, Hopkinton, MA, United States Signer, Ethan R., Cambridge, MA, United States Wakefield, James, Brookline, MA, United States Reed, Michael J., Oak Ridge, TN, United States
PATENT ASSIGNEE(S):	Praecis Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5817626		19981006	<--
APPLICATION INFO.:	US 1995-404831		19950314 (8)	

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Russel, Jeffrey E.
LEGAL REPRESENTATIVE:	Lahive & Cockfield LLP, DeConti, Jr., Guilio A., Kara, Catherine J.
NUMBER OF CLAIMS:	27
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	1324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that act to modulate the aggregation of natural β amyloid peptides (β-AP) are disclosed. The β amyloid modulators of the

invention can promote β-AP aggregation or, more preferably, can inhibit natural β-AP aggregation. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Preferred β amyloid modulators comprise amino-terminally biotinylated β amyloid peptide compounds. Pharmaceutical compositions comprising the compounds of the invention, and methods of altering natural β-AP aggregation using the compounds of the invention, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **182912-78-3P 183746-33-0P 183746-58-9P**
183746-75-0P 183746-77-2P 183746-80-7P
183746-81-8P 183746-89-6P 183746-91-0P
183746-96-5P 183903-86-8P 183903-87-9P
(preparation of peptides as modulators of amyloid aggregation for treating amyloidosis-associated disorders)
RN 182912-78-3 USPATFULL
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-33-0 USPATFULL
CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-58-9 USPATFULL
CN L-Alaninamide, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-75-0 USPATFULL
CN L-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-77-2 USPATFULL
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183746-80-7 USPATFULL
CN L-Alaninamide, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-N-[2-[[(3β,5β,7α,12α)-23-carboxy-7,12-dihydroxy-24-norcholan-3-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-81-8 USPATFULL
CN L-Alanine, N-[(3β,5β,7α,12α)-3-(2-aminoethoxy)-7,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-89-6 USPATFULL
CN L-Alanine, N-[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-91-0 USPATFULL
CN L-Alanine, N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183746-96-5 USPATFULL
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183903-86-8 USPATFULL
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 183903-87-9 USPATFULL
CN D-Alanine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=> d l12 1-12 ibib abs hitstr
L12 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l10 1-12 ibib abs hitstr

L10 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:540135 HCAPLUS
DOCUMENT NUMBER: 137:108295
TITLE: Vaccines comprising all-D fibril peptides for prevention and treatment of Alzheimer's and amyloid-related diseases
INVENTOR(S): Chalifour, Robert; Hebert, Lise; Kong, Xianqi; Gervais, Francine
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 724,842.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094335	A1	20020718	US 2001-867847	20010529 <--
CA 2449056	AA	20021205	CA 2002-2449056	20020529
WO 2002096937	A2	20021205	WO 2002-CA763	20020529
WO 2002096937	A3	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1392728	A2	20040303	EP 2002-729715	20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508863	T2	20050407	JP 2003-500116	20020529
CN 1662554	A	20050831	CN 2002-814967	20020529
US 2005090439	A1	20050428	US 2004-825958	20040416 <--

PRIORITY APPLN. INFO.:

US 1999-168594P	P	19991129 <--
US 2000-724842	A2	20001128
US 2001-867847	A	20010529
WO 2002-CA763	W	20020529

AB The present invention relates to a stereochem. based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens. The vaccine comprises fibril peptides consisting of all- D-amino acids.
IT **342877-91-2 342877-93-4 342877-94-5**
342877-95-6
RL: BSU (Biological study, unclassified); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccines comprising all-D fibril peptides for prevention and treatment of Alzheimer's and amyloid-related diseases)

RN 342877-91-2 HCAPLUS
CN D-Alanine, N-(3-sulfopropyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-93-4 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(2-sulfoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-94-5 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(3-sulfopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-95-6 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(4-sulfobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:597818 HCAPLUS
DOCUMENT NUMBER: 135:185457
TITLE: Methods for enhancing the bioavailability of a drug
INVENTOR(S): Hayward, Neil J.; Gefter, Malcolm L.
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058470	A2	20010816	WO 2001-US104178	20010209 <--
WO 2001058470	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2398567	AA	20010816	CA 2001-2398567	20010209 <--
US 2002142950	A1	20021003	US 2001-781133	20010209 <--
EP 1263454	A2	20021211	EP 2001-910490	20010209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522152	T2	20030722	JP 2001-557578	20010209 <--
US 2005288222	A1	20051229	US 2004-793388	20040303 <--

PRIORITY APPLN. INFO.:

US 2000-181833P	P	20000211 <--
US 2000-181943P	P	20000211 <--
US 2001-781133	B1	20010209
WO 2001-US4178	W	20010209

AB The invention provides methods and compns. for enhancing the bioavailability of a drug in a subject. The present invention also provides methods and compns. for treating or preventing hepatic injury in humans. The invention further provides methods for identifying hydrophobic peptides, e.g., β-amyloid peptide derivs., which are useful in enhancing bioavailability of a drug. Thus, brain levels of PPI-58 were elevated in the presence of cyclosporin A. The biodistribution data demonstrated that higher levels were observed within the

small intestine in the presence of cyclosporin A.

IT **204333-52-8 204333-53-9 204334-00-9**
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(methods for enhancing drug bioavailability)

RN 204333-52-8 HCAPLUS
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-53-9 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204334-00-9 HCAPLUS
CN D-Alaninamide, N-(4-hydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:416788 HCAPLUS
DOCUMENT NUMBER: 135:18553
TITLE: Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
INVENTOR(S): Chalifour, Robert; Hebert, Lise; Kong, Xianqi; Gervais, Francine
PATENT ASSIGNEE(S): Neurochem, Inc., Can.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039796	A2	20010607	WO 2000-CA1413	20001129 <--
WO 2001039796	A3	20011206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388559	AA	20010607	CA 2000-2388559	20001129 <--
BR 2000016022	A	20020806	BR 2000-16022	20001129 <--
EP 1235587	A2	20020904	EP 2000-981111	20001129 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500354	T2	20040108	JP 2001-541528	20001129 <--
NO 2002002531	A	20020712	NO 2002-2531	20020528 <--
US 2005090439	A1	20050428	US 2004-825958	20040416 <--

PRIORITY APPLN. INFO.:
US 1999-168594P P 19991129 <--
US 2000-724842 A 20001128
WO 2000-CA1413 W 20001129

AB The present invention relates to a stereochem. based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

IT **342877-90-1P 342877-91-2P 342877-92-3P**
342877-93-4P 342877-94-5P 342877-95-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccine for prevention and treatment of Alzheimer's and amyloid related diseases using all-D peptides that elicit immune response to amyloid protein)

RN 342877-90-1 HCAPLUS
CN D-Alanine, N-(2-sulfoethyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-91-2 HCAPLUS
CN D-Alanine, N-(3-sulfopropyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-92-3 HCAPLUS
CN D-Alanine, N-(4-sulfobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-93-4 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(2-sulfoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-94-5 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(3-sulfopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-95-6 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(4-sulfobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:78389 HCAPLUS
DOCUMENT NUMBER: 134:131368
TITLE: Preparation of β-amyloid peptide inhibitors
INVENTOR(S): Barnham, Kevin Jeffrey; McCarthy, Thomas David; Pallich, Susanne; Matthews, Barry Ross; Cherny, Robert Alan
PATENT ASSIGNEE(S): Biomolecular Research Institute Ltd., Australia; The University of Melbourne
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007442	A1	20010201	WO 2000-AU886	20000721 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379858	AA	20010201	CA 2000-2379858	20000721 <--
EP 1232159	A1	20020821	EP 2000-945456	20000721 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505462	T2	20030212	JP 2001-512526	20000721 <--
AU 780380	B2	20050317	AU 2000-59548	20000721 <--
PRIORITY APPLN. INFO.:			AU 1999-1804 A	19990723 <--
			WO 2000-AU886 W	20000721

GI



I

AB The present invention relates to compds., such as I (R = BOC-L-Leu-L-Val-L-Phe-L-Phe-L-Ala-) as which inhibit the binding of metal ions to a region in the N-terminal loop of the <b-amyloid peptide which includes a cluster of histidine residues. In addition, the invention relates to pharmaceutical compns. including these compds. as the active agent, and to methods of treatment involving the administration of these compds. The compds. of the invention are useful in the treatment of Alzheimer's disease and other amyloid-related conditions. In a first aspect the present invention provides a compound which interacts with the <b-amyloid peptide in such a way that the N-terminal loop of the peptide (amino acid residues 1-15) is blocked or destabilized, thereby inhibiting the binding of one or more metal ions to at least one histidine residue within the N-terminal loop. Preferably the compound inhibits binding of Cu2+, Zn2+ and Fe3+ ions, but not Mg2+ or Ca2+ ions.

IT **183746-96-5P**, BRI 7077 **321913-14-8P**, BRI 7082
321913-18-2P 321913-19-3P, BRI 7160
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of β-amyloid peptide inhibitors)

RN 183746-96-5 HCAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321913-14-8 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 321913-13-7
CMF C33 H47 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 321913-18-2 HCAPLUS
CN L-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-N-[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 321913-19-3 HCAPLUS
CN L-Alanine, N-[4-(1,4,8,11-tetraazacyclotetradec-1-ylmethyl)benzoyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **321913-16-0P**, BRI 7106 **321913-17-1P**, BRI 7158
321913-20-6P, BRI 7161 **321916-61-4P**, BRI 7159
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amyloid peptide inhibitors)

RN 321913-16-0 HCAPLUS

CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, 3-[5-(1-methyl-2-pyrrolidinyl)-3-pyridinyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321913-17-1 HCAPLUS

CN Nickelate(1-), [N-[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl-κN21,κN22,κN23,κN24)benzoyl]-L-leucyl-L-valyl-L-

phenylalanyl-L-phenylalanyl-L-alaninato(3-)]-, hydrogen, (SP-4-2)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 321913-20-6 HCAPLUS
CN Nickel, diaqua[methyl N-[4-[(1,4,8,11-tetraazacyclotetradec-1-yl-κN1,κN4,κN8,κN11)methyl]benzoyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-L-alaninato(2-)]-, (OC-6-15)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 321916-61-4 HCAPLUS
CN Nickel, [N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-valyl-L-phenylalanyl-ψ-(CH2-NH)-L-phenylalanyl-N-[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl-κ.italN21-24)phenyl]-L-alaninamidato(2-)]-, (SP-4-2)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **321746-99-0P 321747-00-6P 321747-02-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amyloid peptide inhibitors)
RN 321746-99-0 HCAPLUS
CN L-Alanine, N-[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl)benzoyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 321747-00-6 HCAPLUS
CN L-Alanine, N-[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl)benzoyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 321747-02-8 HCAPLUS
CN L-Alanine, N-[4-[[4,8,11-tris[(1,1-dimethylethoxy)carbonyl]-1,4,8,11-tetraazacyclotetradec-1-yl]methyl]benzoyl]-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:628174 HCAPLUS
DOCUMENT NUMBER: 133:221242
TITLE: Modulators of beta-amyloid peptide aggregation comprising D-amino acids
INVENTOR(S): Findeis, Mark A.; Phillips, Kathryn; Olson, Gary L.; Self, Christopher
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052048	A1	20000908	WO 2000-US5574	20000303 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362834	AA	20000908	CA 2000-2362834	20000303 <--
CA 2362834	C	20051206		
EP 1161449	A1	20011212	EP 2000-916028	20000303 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008738	A	20011226	BR 2000-8738	20000303 <--
JP 2002543043	T2	20021217	JP 2000-602272	20000303 <--
US 6610658	B1	20030826	US 2000-519019	20000303 <--
NZ 514414	A	20040227	NZ 2000-514414	20000303 <--
AU 781292	B2	20050512	AU 2000-37196	20000303 <--
RU 2260599	C2	20050920	RU 2001-127246	20000303 <--
ZA 2001007913	A	20020926	ZA 2001-7913	20010926 <--
US 2003236197	A1	20031225	US 2003-395290	20030324 <--
US 6831066	B2	20041214		
US 2005137128	A1	20050623	US 2004-989763	20041115 <--
AU 2005203579	A1	20050908	AU 2005-203579	20050810 <--
PRIORITY APPLN. INFO.:			US 1999-122736P P	19990304 <--
			US 2000-519019 A1	20000303 <--

WO 2000-US5574 W 20000303 <--
US 2003-395290 A1 20030324

AB Compds. that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.

IT **182912-78-3**
RL: PRP (Properties)
(Unclaimed; modulators of beta-amyloid peptide aggregation comprising D-amino acids)
RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **290828-20-5 290828-21-6**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulators of β-amyloid peptide aggregation comprising D-amino acids)
RN 290828-20-5 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 290828-21-6 HCAPLUS
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:732951 HCAPLUS
DOCUMENT NUMBER: 131:346548
TITLE: Modulators of β-amyloid peptide aggregation comprising D-amino acids
INVENTOR(S): Findeis, Mark A.; Gefter, Malcolm L.; Musso, Gary; Signer, Ethan R.; Wakefield, James; Molineaux, Susan; Chin, Joseph; Lee, Jung-ja; Kelley, Michael; Komar-Panicucci, Sonja; Arico-Muendel, Christopher C.; Phillips, Kathryn; Hayward, Neil J.
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., USA
SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 548,998, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985242	A	19991116	US 1997-920162	19970827 <--
US 6303567	B1	20011016	US 1996-703675	19960827 <--
US 6277826	B1	20010821	US 1999-356931	19990719 <--
AU 759036	B2	20030403	AU 2000-35389	20000519 <--
US 2002103134	A1	20020801	US 2001-895443	20010629 <--
US 6689752	B2	20040210		
AU 769915	B2	20040212	AU 2002-15539	20020211 <--
AU 2003208150	A1	20030807	AU 2003-208150	20030703 <--
US 2006014696	A1	20060119	US 2003-677076	20030930 <--
AU 2004202014	A1	20040610	AU 2004-202014	20040512 <--
PRIORITY APPLN. INFO.:			US 1995-548998	B2 19951027 <--
			US 1996-616081	B2 19960314 <--
			US 1996-703675	A 19960827 <--
			US 1997-897342	B2 19970721 <--
			US 1995-404831	A2 19950314 <--
			US 1995-475579	A2 19950607 <--
			AU 1996-52524	A3 19960314 <--
			AU 1997-42387	A3 19970827 <--
			US 1997-920162	A1 19970827 <--

US 1999-356931 A1 19990719 <--
AU 2000-35389 A3 20000519 <--
US 2001-895443 A1 20010629
AU 2002-15539 A3 20020211

OTHER SOURCE(S): MARPAT 131:346548

AB Compds. that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.

IT **204333-38-0 204333-40-4 204333-84-6**
204333-88-0 204333-90-4 204333-91-5
204333-92-6 204333-93-7 204333-95-9
204333-96-0 204333-97-1 204333-98-2
204333-99-3 204334-00-9 204334-01-0
204334-15-6 250370-38-8 250370-43-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulators of β-amyloid peptide aggregation comprising D-amino acids)

RN 204333-38-0 HCAPLUS

CN D-Alaninamide, N-[(3α,5β,6α)-3,6-dihydroxycholan-24-oyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-40-4 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7β)-3,7-dihydroxycholan-24-oyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204333-84-6 HCAPLUS
CN D-Alaninamide, N-[(3,5-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-88-0 HCAPLUS
CN D-Alaninamide, N-(2,4-dihydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-90-4 HCAPLUS
CN D-Alaninamide, hydroxyacetyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-91-5 HCAPLUS
CN D-Alaninamide, N-[3-(2-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 204333-92-6 HCAPLUS
CN D-Alaninamide, N-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

RN 204333-93-7 HCAPLUS
CN D-Alaninamide, N-[3-(3-hydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

—NH_2

RN 204333-95-9 HCAPLUS
CN D-Alaninamide, N-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B

—NH_2

RN 204333-96-0 HCAPLUS
CN D-Alaninamide, N-(3-formylbenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-97-1 HCAPLUS
CN D-Alaninamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 204333-98-2 HCAPLUS
CN D-Alaninamide, N-[(2-formylphenoxy)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-99-3 HCAPLUS

CN D-Alaninamide, N-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 204334-00-9 HCAPLUS
CN D-Alaninamide, N-(4-hydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204334-01-0 HCAPLUS
CN D-Alaninamide, N-[(4-hydroxyphenyl)acetyl]-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 204334-15-6 HCAPLUS
CN D-Alaninamide, α,4-dihydroxybenzenepropanoyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 250370-38-8 HCAPLUS
CN D-Alaninamide, N,N-bis(hydroxyphenylacetyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250370-43-5 HCAPLUS
CN D-Alaninamide, N-[(3α,5β,7α)-3,7-dihydroxycholan-24-oyl]-
D-leucyl-L-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **182912-78-3**
RL: PRP (Properties)

(unclaimed sequence; modulators of β-amyloid peptide aggregation comprising D-amino acids)
RN 182912-78-3 HCAPLUS
CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2005:331237 USPATFULL
TITLE: Methods for enhancing the bioavailability of a drug
INVENTOR(S): Hayward, Neil J., North Grafton, MA, UNITED STATES
Gefter, Malcolm L., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005288222	A1	20051229
APPLICATION INFO.:	US 2004-793388	A1	20040303 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-781133, filed on 9 Feb 2001, ABANDONED

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-181833P	20000211 (60)	<--
	US 2000-181943P	20000211 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions for enhancing the bioavailability of a drug in a subject. The present invention also provides methods and compositions for treating or preventing hepatic injury in a subject in need thereof. The invention further provides methods for identifying hydrophobic peptides, e.g., β-amyloid peptide derivatives, which are useful in enhancing bioavailability of a drug in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **204333-52-8 204333-53-9 204334-00-9**
(methods for enhancing drug bioavailability)
RN 204333-52-8 USPATFULL

CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-53-9 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204334-00-9 USPATFULL
CN D-Alaninamide, N-(4-hydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2005:158918 USPATFULL
TITLE: Modulators of -amyloid peptide aggregation
INVENTOR(S): Findeis, Mark A., Cambridge, MA, UNITED STATES
Phillips, Kathryn, Marlborough, MA, UNITED STATES
Olsen, Gary L., Mountainside, NJ, UNITED STATES

Self, Christopher, West Caldwell, NJ, UNITED STATES
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005137128	A1	20050623
APPLICATION INFO.:	US 2004-989763	A1	20041115 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-395290, filed on 24 Mar 2003, GRANTED, Pat. No. US 6831066 Continuation of Ser. No. US 2000-519019, filed on 3 Mar 2000, GRANTED, Pat. No. US 6610658

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122736P	19990304 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ.sub.17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **182912-78-3**
(Unclaimed; modulators of beta-amyloid peptide aggregation comprising D-amino acids)

RN 182912-78-3 USPATFULL

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **290828-20-5 290828-21-6**
(modulators of β-amyloid peptide aggregation comprising D-amino acids)
RN 290828-20-5 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 290828-21-6 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 9 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2005:105501 USPATFULL
TITLE: Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
INVENTOR(S): Chalifour, Robert, Ile Bizard, CANADA
Hebert, Lise, Montreal Nord, CANADA
Kong, Xianqi, Dollard-des-Ormeaux, CANADA
Gervais, Francine, Ile Bizard, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090439	A1	20050428
APPLICATION INFO.:	US 2004-825958	A1	20040416 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-724842, filed on 28 Nov 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-168594P	19991129 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **342877-90-1P 342877-91-2P 342877-92-3P 342877-93-4P 342877-94-5P 342877-95-6P**
(vaccine for prevention and treatment of Alzheimer's and amyloid related diseases using all-D peptides that elicit immune response to amyloid protein)
RN 342877-90-1 USPATFULL
CN D-Alanine, N-(2-sulfoethyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-91-2 USPATFULL
CN D-Alanine, N-(3-sulfopropyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-92-3 USPATFULL
CN D-Alanine, N-(4-sulfobutyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-93-4 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(2-sulfoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-94-5 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(3-sulfopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342877-95-6 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(4-sulfobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2003:335319 USPATFULL
TITLE:	Modulators of beta-amyloid peptide aggregation
INVENTOR(S):	Findeis, Mark A., Cambridge, MA, UNITED STATES Phillips, Kathryn, Boston, MA, UNITED STATES Olson, Gary L., Mountainside, NJ, UNITED STATES Self, Christopher, West Caldwell, NJ, UNITED STATES
PATENT ASSIGNEE(S):	Praecis Pharmaceuticals Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236197	A1	20031225
	US 6831066	B2	20041214
APPLICATION INFO.:	US 2003-395290	A1	20030324 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-519019, filed on 3 Mar 2000, GRANTED, Pat. No. US 6610658		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122736P	19990304 (60) <--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	2892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably

based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ.sub.17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **182912-78-3**
(Unclaimed; modulators of beta-amyloid peptide aggregation comprising D-amino acids)

RN 182912-78-3 USPATFULL

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **290828-20-5 290828-21-6**
(modulators of β-amyloid peptide aggregation comprising D-amino acids)

RN 290828-20-5 USPATFULL

CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 290828-21-6 USPATFULL

CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2003:228314 USPATFULL
TITLE:	Modulators of μ-amyloid peptide aggregation
INVENTOR(S):	Findeis, Mark A., Cambridge, MA, United States Phillips, Kathryn, Boston, MA, United States Olson, Gary L., Mountainside, NJ, United States Self, Christopher, West Caldwell, NJ, United States
PATENT ASSIGNEE(S):	Praecis Pharmaceuticals Inc., Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6610658	B1	20030826	
APPLICATION INFO.:	US 2000-519019		20000303	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-122736P	19990304 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Low, Christopher S. F.
ASSISTANT EXAMINER:	Kam, Chih-Min
LEGAL REPRESENTATIVE:	Lahive & Cockfield LLP, DeConti, Jr., Giulio A.
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	2884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ.sub.17-21. In certain embodiments, the peptide is modified at the: amino-terminus, carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **182912-78-3**
(Unclaimed; modulators of beta-amyloid peptide aggregation comprising D-amino acids)

RN 182912-78-3 USPATFULL

CN L-Alanine, L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **290828-20-5 290828-21-6**
(modulators of β-amyloid peptide aggregation comprising D-amino acids)

RN 290828-20-5 USPATFULL

CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 290828-21-6 USPATFULL

CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:259378 USPATFULL
TITLE: Methods for enhancing the bioavailability of a drug
INVENTOR(S): Hayward, Neil J., North Grafton, MA, UNITED STATES
Gefter, Malcolm L., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142950	A1	20021003	
APPLICATION INFO.:	US 2001-781133	A1	20010209	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-181833P	20000211 (60)	<--
	US 2000-181943P	20000211 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions for enhancing the bioavailability of a drug in a subject. The present invention also provides methods and compositions for treating or preventing hepatic injury in a subject in need thereof. The invention further provides methods for identifying hydrophobic peptides, e.g., β-amyloid peptide derivatives, which are useful in enhancing bioavailability of a drug in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **204333-52-8 204333-53-9 204334-00-9**
(methods for enhancing drug bioavailability)
RN 204333-52-8 USPATFULL
CN D-Alanine, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204333-53-9 USPATFULL
CN D-Alaninamide, D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204334-00-9 USPATFULL
CN D-Alaninamide, N-(4-hydroxybenzoyl)-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.